zilovertamab vedotin + rituximab + gemcitabine + oxaliplatin

This drug is a **combination regimen** of four active agents: - **zilovertamab vedotin**, an investigational antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), which delivers a cytotoxic payload to ROR1-expressing cancer cells; - **rituximab**, a monoclonal antibody targeting CD20 on B-lymphocytes; - **gemcitabine**, a nucleoside analog and chemotherapeutic agent that inhibits DNA synthesis; - **oxaliplatin**, a platinum-based chemotherapeutic that forms DNA crosslinks and induces apoptosis. The combination of these drugs (ZV + R-GemOx) is being investigated in clinical trials for the treatment of **relapsed or refractory diffuse large B-cell lymphoma (DLBCL)**, particularly in patients who have failed or are ineligible for CAR-T cell therapy and autologous stem cell transplant. This regimen is considered investigational, with emerging evidence of efficacy and safety in phase 2/3 clinical studies[1][3][6].

Other names

ZV + R-GemOxzilovertamab vedotin + R-GemOx